- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Total bilirubin, inexpensive predictor of poor prognosis in new-onset NSTEMI patients: Study
China: Higher myocardial infarction admission total bilirubin (TBIL) is an independent predictor of poor prognosis in patients with new-onset non-ST elevation myocardial infarction (NSTEMI), says a recent study.
The findings of the study, published in the journal BMC Cardiovascular Disorders, support the incorporation of serum TBIL measurement while performing risk stratification for patients with new-onset NSTEMI because of the convenience and cost-effectiveness of measuring serum TBIL.
Prior to the study, there was no clear understanding of the potential prognostic role of TBIL in patients with new-onset NSTEMI. Kezhong Ma, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China, and colleagues aimed to evaluate the potential predictive value of TBIL for long-term prognosis in patients with new-onset NSTEMI.
The study included patients with new-onset NSTEMI that underwent emergency coronary angiography between June 2015 to March 2020. At admission, baseline TBIL were measured. The severity of coronary lesions were indicated by SYNTAX scores.
Multivariate logistic regression was used to analyze the association between TBIL and SYNTAX. The patients were followed for the incidence of major adverse cardiac and cerebrovascular events (MACCEs). Kaplan–Meier survival methods were used to analyze the association between TBIL and MACCEs. A total of 327 patients were included in the study.
Following were the key findings of the study:
- Patients were divided according to tertiles of TBIL (first tertile < 10.23 µmol/L, n = 109; second tertile 10.23–14.30 µmol/L, n = 109; and third tertile ≥ 14.30 µmol/L, n = 109).
- TBIL was independently associated with the severity of coronary lesions in patients with NSTEMI, with an adjusted odd ratio (OR) for the third tertile and the second tertile compared with the first tertile of TBIL of 2.259 and 2.167, respectively.
- After a mean follow-up of 30.33 months, MACCE had occurred in 57 patients.
- TBIL was independently associated with the increased risk of MACCEs, with an adjusted hazard ratio (HR) for the third tertile and the second tertile compared with the first tertile of TBIL of 2.737 and 3.272, respectively.
"The results of this study suggest that myocardial infarction admission TBIL might be an inexpensive predictor of poor prognosis in patients with new-onset NSTEMI," the authors wrote.
Reference:
Yang, Y., Wang, J., Wai Si Ding, A.J.G.L. et al. Serum total bilirubin and long-term prognosis of patients with new-onset non-ST elevation myocardial infarction: a cohort study. BMC Cardiovasc Disord 22, 165 (2022). https://doi.org/10.1186/s12872-022-02607-8
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751